Twist Bioscience Corp (TWST)
NASDAQ:TWST
TWST Stock Chart & Stats
$50.38
-$0.78(-1.71%)
At close: 4:00 PM EST
$50.38
-$0.78(-1.71%)
Day’s Range― - ―
52-Week Range$23.30 - $57.88
Previous CloseN/A
Volume152.02K
Average Volume (3M)1.01M
Market Cap
$2.94B
Enterprise Value$3.12B
Total Cash (Recent Filing)$197.95M
Total Debt (Recent Filing)$183.86M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Apr 30, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding61,311,703
10 Day Avg. Volume914,694
30 Day Avg. Volume1,013,859
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue7.98
Enterprise Value/Gross Profit15.46
Enterprise Value/Ebitda-61.06
Forecast
1Y Price Target
$54.80Price Target Upside8.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$438.86M
Bulls Say, Bears Say
Bulls Say
AI-driven Demand And PartnershipsAnalyst highlights durable AI-driven demand and recent collaborations that position the company as a leader in AI-enabled drug discovery, expanding its potential customer pipeline and revenue opportunity.
B-Body Licensing And BispecificsAnalyst indicates the licensing of Invenra's B-Body bispecific antibody platform broadens service offerings and could generate discovery and licensing revenue with lower development risk due to strong manufacturing yields.
Guidance And Margin ImprovementAnalyst reports management raised revenue guidance and surpassed revenue and gross margin expectations, reinforcing a clearer path to adjusted profitability and supporting a potential valuation re-rating versus peers.
Bears Say
AI-related Wet Lab RiskAnalyst highlights investor concern about AI-related risks to wet lab drug discovery that could raise uncertainty around future demand for laboratory services.
Customer Concentration And TransitionAnalyst warns that a transition with a large oncology diagnostics customer reduced growth, highlighting customer concentration risk that can depress near-term revenue.
Profitability Pressure From InvestmentsAnalyst cautions that investments to scale capabilities for AI-related demand have increased losses on an adjusted basis, creating near-term profitability pressure.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience Corp’s price range in the past 12 months?
Twist Bioscience Corp lowest stock price was $23.30 and its highest was $57.88 in the past 12 months.
What is Twist Bioscience Corp’s market cap?
Twist Bioscience Corp’s market cap is $2.94B.
When is Twist Bioscience Corp’s upcoming earnings report date?
Twist Bioscience Corp’s upcoming earnings report date is Apr 30, 2026 which is in 16 days.
How were Twist Bioscience Corp’s earnings last quarter?
Twist Bioscience Corp released its earnings results on Feb 02, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.424 by -$0.076.
Is Twist Bioscience Corp overvalued?
According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued.
Does Twist Bioscience Corp pay dividends?
Twist Bioscience Corp does not currently pay dividends.
What is Twist Bioscience Corp’s EPS estimate?
Twist Bioscience Corp’s EPS estimate is -0.48.
How many shares outstanding does Twist Bioscience Corp have?
Twist Bioscience Corp has 61,311,703 shares outstanding.
What happened to Twist Bioscience Corp’s price movement after its last earnings report?
Twist Bioscience Corp reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.424. Following the earnings report the stock price went up 13.976%.
Which hedge fund is a major shareholder of Twist Bioscience Corp?
Currently, no hedge funds are holding shares in TWST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.80 (8.77% Upside)
$54.80 (8.77% Upside)
Blogger Sentiment
Neutral
TWST Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.67%
12-Months-Change
Fundamentals
Return on Equity
-16.58%
Trailing 12-Months
Asset Growth
4.85%
Trailing 12-Months
Company Description
Twist Bioscience Corp
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
TWST Company Deck
TWST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized continued, broad-based revenue growth (Q1 revenue +17% YoY), margin expansion (gross margin 52%, +~4 pts YoY), accelerating demand from AI-enabled discovery (notably 27% growth in DNA synthesis & protein solutions and meaningful gene/data volumes), and raised fiscal 2026 guidance with a reiterated commitment to adjusted EBITDA breakeven. Headline negatives include a continuing adjusted EBITDA loss, increased operating spend to fund growth, some customer concentration in NGS (previous single-customer volatility), and near-term margin moderation from new product launches. On balance, management portrayed strong operational momentum and a clear path to profitability while intentionally investing to capture growth opportunities.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$54.80
▲(8.77% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---